Approval · Notice of Compliance 9711 · 2008
DILAUDID: Notice of Compliance 9711
Issued August 8, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9711
- Date
- August 8, 2008
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Opioid analgesic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DILAUDID | 02085895 | Cancelled Post Market |
| DILAUDID-HP | 00622133 | Cancelled Post Market |
| DILAUDID-HP PLUS | 02146118 | Cancelled Post Market |
| DILAUDID-XP | 02145863 | Cancelled Post Market |
Medicinal ingredients
- HYDROMORPHONE HCL 250 MG per VIAL
- HYDROMORPHONE HCL 10 MG per ML
- HYDROMORPHONE HCL 20 MG per ML
- HYDROMORPHONE HCL 50 MG per ML